Infusion Nurses - VITAL™ Training for Administering Sub-Q Therapy

VITAL™ training program for healthcare professionals

CSL Behring is committed to supporting healthcare professionals who choose to move their patients to the Sub-Q way. That’s why we developed VITAL^™, the “Vivaglobin Integrated Training and Learning” program. The program provides information about Sub-Q therapy, dosing considerations, and hands-on training with ambulatory infusion pumps and tubing.

While the VITAL^™ program can assist nurses in learning best practices needed to effectively train patients for self-administration of their Sub-Q Ig therapy, we recognize that there’s always new information to learn.

As the VITAL^™ program is developed, you will find new information on the expanding world of Sub-Q Ig therapy:

Investigate key issues surrounding the nurse's expanding role in the field of infusion therapy
Review approaches to matching patients with the appropriate treatment modes
Examine key components of patient training and compliance
Learn ways to maximize positive patient experiences

At CSL Behring, we understand the expanding role of infusion nursing professionals and their critical link to improving patient care. We are committed to providing healthcare professionals like you with extensive tools and information to help you advance your knowledge of self-administered therapies.

VITAL™ resources

Click here to view the Vivaglobin^® self-administration video
Access the Vivaglobin^® online training Web site by visiting www.vivaglobinaccess.com
Register for the VITAL^™ e-newsletter offering case studies, helpful tips, updates on clinical research, and more

Important Safety Information

Immune Globulin Subcutaneous (Human), Vivaglobin^®, is indicated for the treatment of patients with primary immunodeficiency (PI).

As with all immune globulin products, Vivaglobin^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations and in persons with selective immunoglobulin A deficiency who have known antibody against IgA. If anaphylactic or anaphylactoid reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Vivaglobin^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical trials, the most frequent adverse event was injection-site reaction, consisting of mild or moderate swelling, redness, and itching. No serious local site reactions were observed, and reactions tended to decrease substantially after repeated use. Other adverse events irrespective of causality included headache, gastrointestinal disorder, fever, nausea, sore throat, and rash.

As with all immune globulin (Ig) products, patients receiving Ig therapy for the first time, receiving a new product, or not having received Ig therapy within the preceding eight weeks may be at risk for developing reactions including fever, chills, nausea, and vomiting. On rare occasions, these reactions may lead to shock. Such patients should be monitored in a clinical setting during the initial administration.

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella.

In clinical studies, administration of Vivaglobin^® has been shown to be safe and well tolerated in both adult and pediatric subjects. No pediatric-specific dose requirements were necessary to achieve the desired serum IgG levels. Safety and efficacy were not studied in pediatric subjects under two years of age.

Please see accompanying full prescribing information for Vivaglobin^®.

Please see Patient Product Information

Please see full Prescribing Information

VITAL™ training program for healthcare professionals

Important Safety Information

Please see accompanying full prescribing information for Vivaglobin®.

Please see accompanying full prescribing information for Vivaglobin^®.